Why the study?
Does the chromogenic factor X assay accurately predict a therapeutic INR in patients transitioning from argatroban to warfarin therapy?
Does the chromogenic factor X assay accurately predict a therapeutic INR in patients transitioning from argatroban to warfarin therapy?
Measuring chromogenic factor X levels (targeting ≤45%) alongside at least 5 days of warfarin overlap can help safely guide the transition from argatroban to warfarin therapy.
May support chromogenic factor X monitoring during argatroban-warfarin overlap; leaves open need for prospective validation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Stearns et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: